 IRVINE, Calif.--BUSINESS WIRE--Axonics Modulation Technologies, Inc. NASDAQ: AXNX, a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation SNM devices for the treatment of urinary and bowel dysfunction, today reported preliminary unaudited net revenue for the three months and fiscal year ended December 31, 2020. Preliminary unaudited net revenue is expected to be in the range of 34.7 to 34.9 million in the fourth quarter 2020, as c 